Neuroimaging in bipolar disorder: what have we learned?

New technologies are offering increasingly powerful means to obtain structural, chemical, and functional images of the brain during life, often without the use of ionizing radiation. Bipolar disorder, with its clear physiologic features, would appear to be a prime candidate for the application of current brain imaging; however, only a modest number of studies have been reported to date, and most studies have small sample sizes and heterogeneous subject groups. Nonetheless, there are a few consistent findings among these studies, including the following: 1) Structural imaging studies suggest an increased number of white matter hyperintensities in patients with bipolar disorder. These may be lesions unique to bipolar disorder and its treatment, or related to cardiovascular risk factors, which are more common in bipolar patients. Decreased cerebellar size and anomalies of cerebellar blood volume have also been reported. Increased sulcal prominence and enlargement of the lateral and third ventricles are less consistently observed findings. 2) Spectroscopic imaging suggests abnormalities of metabolism of choline-containing compounds in symptomatically ill bipolar patients and, possibly, treatment-induced changes in choline- and myoinositol-containing compounds. Each of these groups of metabolites serves as a component of membrane phospholipids and cellular second-messenger cycles. 3) Metabolic and blood flow studies provide evidence for decreased activity of the prefrontal cortex (PFC) in bipolar patients during depression. It is not clear if these changes are restricted to particular subregions of the PFC, nor if they are reversed with mania. No single pathophysiologic mechanism yet explains these findings, although all might be due to regional alterations in cellular activity and metabolism or changes in cell membrane composition and turnover. The development of imaging technologies has far outpaced their use in bipolar disorder. The promise of future studies is great, with more powerful magnetic resonance scanners, additional ligands for positron emission tomography and single photon emission computed tomography imaging, and improved image generation and processing already available.

[1]  B. Woods,et al.  Age-related MRI abnormalities in bipolar illness: A clinical study , 1995, Biological Psychiatry.

[2]  S. Strakowski,et al.  Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. , 1998, The Journal of clinical psychiatry.

[3]  N. Kato,et al.  Magnetic resonance spectroscopy in affective disorders. , 1998, The Journal of neuropsychiatry and clinical neurosciences.

[4]  Genetics and mental disorders. National Institute of Mental Health's Genetics Workgroup. , 1999, Biological psychiatry.

[5]  Klaus P. Ebmeier,et al.  Limbic Dysfunction in Schizophrenia and Mania , 1996, British Journal of Psychiatry.

[6]  P. Renshaw,et al.  Quantitation of dexfenflurainine/d‐norfenfluramine concentration in primate brain using 19F NMR spectroscopy , 1998, Magnetic resonance in medicine.

[7]  R. Post,et al.  Functional Brain Imaging, Limbic Function, and Affective Disorders , 1996 .

[8]  B. Mazoyer,et al.  The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine , 1999, Biological Psychiatry.

[9]  R. Turner,et al.  Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J S Duncan,et al.  Positron emission tomography receptor studies in epilepsy. , 1999, Revue neurologique.

[11]  L. Altshuler,et al.  T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. , 1995, The American journal of psychiatry.

[12]  Melissa P. DelBello,et al.  MRI Analysis of the Cerebellum in Bipolar Disorder: A Pilot Study , 1999, Neuropsychopharmacology.

[13]  J. Soares,et al.  The anatomy of mood disorders—review of structural neuroimaging studies , 1997, Biological Psychiatry.

[14]  S. Raz Structural Brain Abnormalities in the Major Psychoses , 1989 .

[15]  L W Jelinski,et al.  Nuclear magnetic resonance spectroscopy. , 1995, Academic radiology.

[16]  P R Luyten,et al.  Broadband proton decoupling in human 31p NMR spectroscopy , 1989, NMR in biomedicine.

[17]  P F Renshaw,et al.  In vivo detection of GABA in human brain using a localized double‐quantum filter technique , 1997, Magnetic resonance in medicine.

[18]  S. Rauch,et al.  Neuroimaging and Neurobiological Models of Depression , 1997, Harvard review of psychiatry.

[19]  K. Krishnan,et al.  Structural changes in the brain of patients with bipolar affective disorder by MRI: A review of the literature , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  J. Price,et al.  Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders , 1998, Molecular Psychiatry.

[21]  R. Shulman,et al.  Localized 1H NMR spectra of glutamate in the human brain , 1992, Magnetic resonance in medicine.

[22]  B. Rosen,et al.  Susceptibility contrast imaging of cerebral blood volume: Human experience , 1991, Magnetic resonance in medicine.

[23]  J. Schmahmann,et al.  The cerebellar cognitive affective syndrome. , 1998, Brain : a journal of neurology.

[24]  H. Nasrallah,et al.  Cortical atrophy in schizophrenia and mania: a comparative CT study. , 1982, The Journal of clinical psychiatry.

[25]  K. Botteron,et al.  MRI abnormalities in adolescent bipolar affective disorder. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  R. Kikinis,et al.  Subgenual cingulate cortex volume in first-episode psychosis. , 1999, The American journal of psychiatry.

[27]  S. Dager,et al.  Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. , 1998, The American journal of psychiatry.

[28]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[29]  Hermann-Josef Gertz,et al.  Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs , 1999, Psychiatry Research: Neuroimaging.

[30]  M. Iyo,et al.  Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β‐CFT binding with positron emission tomography , 1999, Annals of neurology.

[31]  L. DeLisi,et al.  Computed tomography in schizophreniform disorder and other acute psychiatric disorders. , 1982, Archives of general psychiatry.

[32]  M. Kraut,et al.  Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  S. Lippmann,et al.  Cerebellar vermis dimensions on computerized tomographic scans of schizophrenic and bipolar patients. , 1982, The American journal of psychiatry.

[34]  P. Videbech MRI findings in patients with affective disorder: a meta‐analysis , 1997, Acta psychiatrica Scandinavica.

[35]  S. Bluml In VivoQuantitation of Cerebral Metabolite Concentrations Using Natural Abundance13C MRS at 1.5 T , 1999 .

[36]  N Sailasuta,et al.  Proton spectroscopy without water suppression: The oversampled J‐resolved experiment , 1998, Magnetic resonance in medicine.

[37]  P. Renshaw,et al.  Differences in Cerebellar Blood Volume in Schizophrenia and Bipolar Disorder , 1998, NeuroImage.

[38]  J. Ehrhardt,et al.  Structural brain abnormalities in bipolar affective disorder. Ventricular enlargement and focal signal hyperintensities. , 1990, Archives of general psychiatry.

[39]  H. Pasantes‐Morales,et al.  Taurine: an osmolyte in mammalian tissues. , 1998, Advances in experimental medicine and biology.

[40]  K. Krishnan,et al.  Subcortical hyperintensities on brain magnetic resonance imaging: a comparison of normal and bipolar subjects. , 1991, The Journal of neuropsychiatry and clinical neurosciences.

[41]  R B Noto,et al.  Advances in nuclear medicine: current concepts. , 1999, Medicine and health, Rhode Island.

[42]  J D Speelman,et al.  One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  N. Raz,et al.  Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. , 1990, Psychological bulletin.

[44]  J A Sorenson,et al.  3D localized 2D NMR spectroscopy on an MRI scanner. , 1995, Journal of magnetic resonance. Series B.

[45]  Hitoshi Shinotoh,et al.  Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age , 1999, European Journal of Nuclear Medicine.

[46]  A. J. Kumar,et al.  Basal ganglia volumes and white matter hyperintensities in patients with bipolar disorder. , 1994, The American journal of psychiatry.

[47]  T. Inubushi,et al.  Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder , 1994, Psychiatry Research: Neuroimaging.

[48]  Michael J. Berridge,et al.  Neural and developmental actions of lithium: A unifying hypothesis , 1989, Cell.

[49]  P. Renshaw,et al.  Applications of functional MR imaging to research in psychiatry. , 1999, Neuroimaging clinics of North America.

[50]  P. Murali Doraiswamy,et al.  Brain imaging in clinical psychiatry , 1997 .

[51]  S. Barondes Report of the National Institute of Mental Health’s Genetics Workgroup Introduction , 1999, Biological Psychiatry.

[52]  Karl J. Friston,et al.  Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[53]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[54]  M. Garwood,et al.  Simultaneous in vivo spectral editing and water suppression , 1998, NMR in biomedicine.

[55]  J. Zubieta,et al.  Gender and age influences on human brain mu-opioid receptor binding measured by PET. , 1999, The American journal of psychiatry.

[56]  K. Krishnan,et al.  Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. , 1996, Depression.

[57]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[58]  Chie Seki,et al.  Effect of tracer metabolism on PET measurement of [11C]pyrilamine binding to histamine H1 receptors , 1999, Annals of nuclear medicine.

[59]  D. Kupfer,et al.  Pet imaging of serotonin 1A receptor binding in depression , 1999, Biological Psychiatry.

[60]  H. Okazawa,et al.  The Validity of the PET/α [11C] Methyl-L-Serotonin Synthesis in the Human Brain , 1999, Neuropsychopharmacology.

[61]  A. Stoll,et al.  The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls: An in vivo proton magnetic resonance spectroscopy study , 1992, Biological Psychiatry.

[62]  C Crouzel,et al.  Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  B Vikhoff-Baaz,et al.  Performance of 2D 1H spectroscopic imaging of the brain: some practical considerations regarding the measurement procedure. , 1999, Magnetic resonance imaging.

[64]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[65]  J Star-Lack,et al.  High spatial resolution and speed in MRSI , 1997, NMR in biomedicine.

[66]  M. Bárány,et al.  Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients , 1992, Schizophrenia Research.

[67]  B. Rosen,et al.  Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.

[68]  R. Baldessarini Drugs and the treatment of psychiatric disorders , 1996 .

[69]  K. Krishnan,et al.  Hyperintense lesions on magnetic resonance images in bipolar disorder , 1999, Biological Psychiatry.

[70]  R. Shulman,et al.  Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[71]  P. Allen,et al.  A new multiple quantum filter design procedure for use on strongly coupled spin systems found in vivo: Its application to glutamate , 1998, Magnetic resonance in medicine.

[72]  A. Scialli Goodman and Gilman's the pharmacologic basis of therapeutics , 1991 .

[73]  P. Renshaw,et al.  Applications of Dynamic Susceptibility Contrast Magnetic Resonance Imaging in Neuropsychiatry , 1996, NeuroImage.

[74]  D. Wong,et al.  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. , 1999, Nuclear medicine and biology.

[75]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[76]  B. Woods,et al.  Structural brain abnormalities in first-episode mania , 1993, Biological Psychiatry.

[77]  R. Heath,et al.  Gross Pathology of the Cerebellum in Patients Diagnosed and Treated as Functional Psychiatric Disorders , 1979, The Journal of nervous and mental disease.

[78]  H. Nasrallah,et al.  Cerebral venticular enlargement in young manic males , 1982 .

[79]  G. Pearlson,et al.  In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. , 1995, Archives of general psychiatry.

[80]  G. Fein,et al.  Abnormal frontal lobe phosphorous metabolism in bipolar disorder. , 1995, The American journal of psychiatry.

[81]  H. Nasrallah,et al.  Cerebral ventricular enlargement in young manic males. A controlled CT study. , 1982, Journal of affective disorders.

[82]  R. Langevin,et al.  Deficits in gray matter volume are present in schizophrenia but not bipolar disorder 1 This work was presented at the Meeting of the Society of Biological Psychiatry, Philadelphia, PA, USA, May 1994. 1 , 1997, Schizophrenia Research.

[83]  P. Grant,et al.  Diffusion MR imaging. Theory and applications. , 1999, Neuroimaging clinics of North America.

[84]  C. Parsons,et al.  Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. , 1999, Journal of receptor and signal transduction research.

[85]  R. Robinson,et al.  Manic-depressive and pure manic states after brain lesions , 1991, Biological Psychiatry.

[86]  David C. Steffens,et al.  Structural neuroimaging and mood disorders: Recent findings, implications for classification, and future directions , 1998, Biological Psychiatry.

[87]  J. Mazziotta,et al.  Reduction of prefrontal cortex glucose metabolism common to three types of depression. , 1989, Archives of general psychiatry.

[88]  J. Karp,et al.  In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates , 1999, European Journal of Nuclear Medicine.

[89]  N. Andreasen,et al.  Cerebellar atrophy in schizophrenia and affective disorder. , 1987, The American journal of psychiatry.

[90]  J. Links,et al.  Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. , 1985, Psychopharmacology bulletin.

[91]  P Boesiger,et al.  Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. , 1999, Magnetic resonance imaging.

[92]  Andrew W. Douglas,et al.  MRI subcortical signal hyperintensities in Mania at first hospitalization , 1993, Biological Psychiatry.

[93]  C. Hanstock,et al.  Effects of lithium and amphetamine on inositol metabolism in the human brain as measured by 1H and 31P MRS , 1999, Biological Psychiatry.

[94]  A. Snyder,et al.  Quantitative diffusion-tensor anisotropy brain MR imaging: normative human data and anatomic analysis. , 1999, Radiology.

[95]  M. Roy,et al.  Dégénérescence cérébelleuse secondaire à une intoxication aiguë au lithium. , 1998 .

[96]  S. Kennedy,et al.  A Review of Functional Neuroimaging in Mood Disorders: Positron Emission Tomography and Depression , 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[97]  J S Taylor,et al.  Proton‐decoupled 31P chemical shift imaging of the human brain in normal volunteers , 1993, NMR in biomedicine.

[98]  Justin S. Smith,et al.  Quantification of δ-Opioid Receptors in Human Brain with N1′ -([11C]Methyl) Naltrindole and Positron Emission Tomography , 1999 .

[99]  W C Eckelman,et al.  Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. , 1999, Life sciences.

[100]  Richard J Davidson,et al.  Regional brain function, emotion and disorders of emotion , 1999, Current Opinion in Neurobiology.

[101]  P. Renshaw,et al.  Effects of myo-Inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study , 1999, Biological Psychiatry.

[102]  J. Mann,et al.  The functional neuroanatomy of mood disorders. , 1997, Journal of psychiatric research.

[103]  D. Jeste,et al.  Neuroanatomical Studies of Major Affective Disorders , 1988, British Journal of Psychiatry.

[104]  S. Rauch,et al.  Clinical Neuroimaging in Psychiatry , 1995, Harvard review of psychiatry.

[105]  W. Yates,et al.  Cardiovascular risk factors in affective disorder. , 1987, Journal of affective disorders.